Stay updated on Pembrolizumab in 1st Line NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in 1st Line NSCLC Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    Revision: v3.4.3 has been added, replacing the previous v3.4.2. This is a minor UI/version update and does not change study details or user interactions on the page.
    Difference
    0.0%
    Check dated 2026-03-11T14:42:58.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.4.2 is now shown; notices about government funding lapses and Revision: v3.4.1 respectively have been removed.
    Difference
    0.3%
    Check dated 2026-02-11T02:22:12.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    Added a notice about a lapse in government funding and updated the revision to v3.4.1. The previous revision v3.4.0 was removed.
    Difference
    0.3%
    Check dated 2026-02-03T23:04:17.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    Added a glossary display option and updated several labels to capitalize consistently (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and updated the revision tag from v3.3.4 to v3.4.0.
    Difference
    0.2%
    Check dated 2026-01-27T21:52:56.000Z thumbnail image
  8. Check
    89 days ago
    Change Detected
    Summary
    The Locations section now lists additional Japanese sites: Aichi-ken, Fukuoka, Hyōgo, Ishikawa-ken, Osaka, and Shizuoka. Location-specific entries were removed and the revision updated to v3.3.3.
    Difference
    0.6%
    Check dated 2025-12-23T07:32:08.000Z thumbnail image
  9. Check
    111 days ago
    Change Detected
    Summary
    The page now shows revision v3.3.2 replacing v3.3.1; no study details or results are affected. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:31:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in 1st Line NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in 1st Line NSCLC Clinical Trial page.